Evidence map›Paper›PMID 20606150›Full record

ArticleJAMA2010

Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease.

Rhonda M Cooper-DeHoff, Yan Gong, Eileen M Handberg, Anthony A Bavry, Scott J Denardo, George L Bakris, Carl J Pepine

3 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in JAMA, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 229 papers, 17 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
229citing papers in PubMed, 17 pooled it
57.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02633488 nacompletedstarted 2014, after this paper: background citation

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

Ran2014Enrolled19Registered outcomes1Posted comparisons1ConditionsInsulin Sensitivity, Metabolic SyndromeArmsMetformin, Placebos
Open the trial in the graph
NCT00133692 phase4completednot on this map

INternational VErapamil SR Trandolapril STudy

TypeinterventionalSponsorUniversity of FloridaRan1997 to 2003Enrolled22,000ConditionsHypertension, Coronary Artery DiseaseArmsVerapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ), Atenolol/HCTZ/Trandolapril
NCT00246519 phase4completednot on this map

Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR)

TypeinterventionalSponsorUniversity of FloridaRan2005 to 2010Enrolled1,701ConditionsHypertensionArmsHydrochlorothiazide, Atenolol
3 · Its place in the literature

Who cites it

229 citing papers in PubMed, 17 syntheses or guidelines pooled it, 661 citations in OpenAlex.

  1. Blood pressure targets for hypertension in people with diabetes mellitus.The Cochrane database of systematic reviews · 2026
    Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Guideline
  7. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Guideline
  8. Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline.The Journal of clinical endocrinology and metabolism · 2019
    Guideline
  9. Guideline
  10. Guideline
  11. Pooled it
  12. Guideline
  13. Blood pressure targets for hypertension in people with diabetes mellitus.The Cochrane database of systematic reviews · 2013
    Pooled it
  14. Pooled it
  15. Guideline
  16. Pooled it
  17. Guideline
  18. Trial
  19. Trial
  20. Trial

169 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Rhonda M Cooper-DeHoffDepartment of Pharmacotherapy and Translational Research and Division of Cardiovascular Medicine, College of Pharmacy, University of Florida, 1600 SW Archer Rd, PO Box 100486, Gainesville, FL 32610-0486, USA. dehoff@cop.ufl.edu
Yan Gong
Eileen M Handberg
Anthony A Bavry
Scott J Denardo
George L Bakris
Carl J Pepine
University of Florida · USFlorida College · USUniversity of Chicago · US

Funding

Pharmacogenomic Evaluation of Antihypertensive ResponsesU01GM074492 · NIGMS · UNIVERSITY OF FLORIDA · PI JOHNSON, JULIE A. · 2005 to 2014
$20.7M
Metabolic Effects of Antihypertensive DrugsK23HL086558 · NHLBI · UNIVERSITY OF FLORIDA · PI COOPER-DEHOFF, RHONDA M · 2007 to 2011
$672k
NHLBI NIH HHS K23 HL086558NHLBI NIH HHS K23HL086558NIGMS NIH HHS U01 GM074492PHS HHS U0IGM074492
6 · The paper itself

Abstract

contextHypertension guidelines advocate treating systolic blood pressure (BP) to less than 130 mm Hg for patients with diabetes mellitus; however, data are lacking for the growing population who also have coronary artery disease (CAD).

objectiveTo determine the association of systolic BP control achieved and adverse cardiovascular outcomes in a cohort of patients with diabetes and CAD. DESIGN, SETTING, AND PATIENTS: Observational subgroup analysis of 6400 of the 22,576 participants in the International Verapamil SR-Trandolapril Study (INVEST). For this analysis, participants were at least 50 years old and had diabetes and CAD. Participants were recruited between September 1997 and December 2000 from 862 sites in 14 countries and were followed up through March 2003 with an extended follow-up through August 2008 through the National Death Index for US participants.

interventionPatients received first-line treatment of either a calcium antagonist or beta-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or both to achieve systolic BP of less than 130 and diastolic BP of less than 85 mm Hg. Patients were categorized as having tight control if they could maintain their systolic BP at less than 130 mm Hg; usual control if it ranged from 130 mm Hg to less than 140 mm Hg; and uncontrolled if it was 140 mm Hg or higher.

main outcome measuresAdverse cardiovascular outcomes, including the primary outcomes which was the first occurrence of all-cause death, nonfatal myocardial infarction, or nonfatal stroke.

resultsDuring 16,893 patient-years of follow-up, 286 patients (12.7%) who maintained tight control, 249 (12.6%) who had usual control, and 431 (19.8%) who had uncontrolled systolic BP experienced a primary outcome event. Patients in the usual-control group had a cardiovascular event rate of 12.6% vs a 19.8% event rate for those in the uncontrolled group (adjusted hazard ratio [HR], 1.46; 95% confidence interval [CI], 1.25-1.71; P < .001). However, little difference existed between those with usual control and those with tight control. Their respective event rates were 12.6% vs 12.7% (adjusted HR, 1.11; 95% CI, 0.93-1.32; P = .24). The all-cause mortality rate was 11.0% in the tight-control group vs 10.2% in the usual-control group (adjusted HR, 1.20; 95% CI, 0.99-1.45; P = .06); however, when extended follow-up was included, risk of all-cause mortality was 22.8% in the tight control vs 21.8% in the usual control group (adjusted HR, 1.15; 95% CI, 1.01-1.32; P = .04).

conclusionTight control of systolic BP among patients with diabetes and CAD was not associated with improved cardiovascular outcomes compared with usual control.

trial registrationclinicaltrials.gov Identifier: NCT00133692.

Indexed as

Blood PressureAgedAntihypertensive AgentsCohort StudiesCoronary Artery DiseaseDiabetes ComplicationsDiabetes MellitusFemaleHumansHypertensionMaleMiddle AgedMyocardial InfarctionRandomized Controlled Trials as TopicRiskStrokeAntihypertensive Agents

Identifiers

PMID20606150
PMCPMC3008411
OpenAlexW2048695535

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.